Compare Amphastar Pharmaceuticals Inc (AMPH) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Sibanye Stillwater Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Sibanye Stillwater Ltd trades at $10.61 (market cap $7.61B). The key difference: Sibanye Stillwater Ltd is far larger — about 8.8× Amphastar Pharmaceuticals Inc's market cap, and Sibanye Stillwater Ltd pays a 2.91% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SBSW | |
|---|---|---|
Market Cap | $863.95M | $7.61B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $21.12 |
52-Week Low | $16.87 | $7.27 |
Enterprise Value | $1.26B | $9.26B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Sibanye Stillwater (SBSW) surged 7.6% to $10.64, showing strong momentum despite negative profitability metrics. The stock trades at attractive valuation multiples with P/E of 4.76 and P/S of 0.95, while technical indicators signal bullish momentum. Recent earnings misses contrast with analyst optimism, with 42.9% recommending Buy and a $14.25 consensus target. The company faces challenges with negative net income margins but shows improving cash flow projections for 2025.
SBSW presents a value opportunity with deep undervaluation metrics, though profitability concerns and recent earnings misses warrant caution. The bullish technical setup and analyst support suggest potential upside, but investors must weigh the company's debt reduction progress against persistent negative margins. Key catalysts include PGM price recovery and management's debt reduction targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
